Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes

Background: Dietary influences on oxidative stress have been thought to play important role in the etiology of PD. Objective: To examine associations of PD with dietary nutrients, including minerals, vitamins, and fats. Methods: A population-based case-control study was conducted among newly diagnosed case (n = 250) and control subjects (n = 388) identified between 1992 and 2002 from enrollees of the Group Health Cooperative health maintenance organization in western Washington state. Controls were frequency matched to cases on sex and age. In-person interviews elicited data on food frequency habits during most of adult life. Nutrient intakes were calculated and analyzed by adjusting each person’s nutrient intake by their total energy intake (the nutrient density technique). Results: Subjects with an iron intake in the highest quartile compared with those in the lowest quartile had an increased risk of PD (odds ratio = 1.7, 95% CI: 1.0, 2.7, trend p = 0.016). There was an apparent joint effect of iron and manganese; dietary intake above median levels of both together conferred a nearly doubled risk compared with lower intakes of each nutrient (odds ratio = 1.9, 95% CI: 1.2, 2.9). No strong associations were found for either antioxidants or fats. Conclusion: A high intake of iron, especially in combination with high manganese intake, may be related to risk for PD.

[1]  J. Jankovic,et al.  Olanzapine treatment for dopaminergic‐induced hallucinations , 2002, Movement disorders : official journal of the Movement Disorder Society.

[2]  J. Friedman,et al.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease , 2002, Biological Psychiatry.

[3]  T. Hislop,et al.  Differential misclassification bias and dietary recall for the distant past using a food frequency questionnaire. , 1990, Nutrition and cancer.

[4]  T. M. Brown.  Clozapine for drug-induced psychosis in Parkinson's disease. , 1999, The New England journal of medicine.

[5]  P. O'Suilleabhain,et al.  Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease , 2000, Neurology.

[6]  P. Riederer,et al.  Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? , 1994, Journal of neurochemistry.

[7]  J. Freudenheim,et al.  Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[8]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[9]  S. Leurgans,et al.  Prospective longitudinal assessment of hallucinations in Parkinson’s disease , 2001, Neurology.

[10]  C. Tanner,et al.  Early dopaminergic drug-induced hallucinations in parkinsonian patients , 1998, Neurology.

[11]  Juliek . Andersen,et al.  The Role of Iron in Parkinson Disease and 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Toxicity , 1999, IUBMB life.

[12]  G. Ulm,et al.  Diet and Parkinson's disease II , 1996, Neurology.

[13]  Karen Marder,et al.  Dietary lipids and antioxidants in Parkinson's disease: A population‐based, case‐control study , 1996, Annals of neurology.

[14]  R. Ratan,et al.  Ironing-out mechanisms of neuronal injury under hypoxic-ischemic conditions and potential role of iron chelators as neuroprotective agents. , 2000, Antioxidants & redox signaling.

[15]  D Spiegelman,et al.  Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk , 2002, Neurology.

[16]  C. C. Johnson,et al.  Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.

[17]  J. Mink,et al.  Welding-related parkinsonism , 2001, Neurology.

[18]  J. Langston,et al.  Epidemiology versus genetics in parkinson's disease: Progress in resolving an age‐old debate , 1998, Annals of neurology.

[19]  D. Morens,et al.  Case‐control study of idiopathic Parkinson's disease and dietary vitamin E intake , 1996, Neurology.

[20]  Gregory G. Brown,et al.  Occupational exposures to metals as risk factors for Parkinson's disease , 1997, Neurology.

[21]  A. Wolk,et al.  Reliability of retrospective information on diet 20 years ago and consistency of independent measurements of remote adolescent diet. , 1997, Nutrition and cancer.

[22]  A. Seidler,et al.  Diet and Parkinson's disease I , 1996, Neurology.

[23]  J. Cummings,et al.  Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[24]  D J Brooks,et al.  An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.

[25]  L. Golbe,et al.  Follow‐up study of early‐life protective and risk factors in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[26]  Nora D Volkow,et al.  The role of dopamine in motivation for food in humans: implications for obesity , 2002, Expert opinion on therapeutic targets.

[27]  N. Volkow,et al.  “Nonhedonic” food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect , 2002, Synapse.

[28]  A. Hofman,et al.  Dietary antioxidants and Parkinson disease. The Rotterdam Study. , 1997, Archives of neurology.

[29]  C. C. Johnson,et al.  Adult nutrient intake as a risk factor for Parkinson's disease. , 1999, International journal of epidemiology.

[30]  S. Factor,et al.  The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia , 2002, Movement disorders : official journal of the Movement Disorder Society.

[31]  S. Leucht.  Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. , 2001, Neurology.

[32]  Jean Logan,et al.  Brain dopamine and obesity , 2001, The Lancet.

[33]  H Checkoway,et al.  Dietary factors in Parkinson's disease: The role of food groups and specific foods , 1999, Movement disorders : official journal of the Movement Disorder Society.

[34]  J. Friedman,et al.  Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial , 2001, Movement disorders : official journal of the Movement Disorder Society.

[35]  K. Marder,et al.  Dietary iron, animal fats, and risk of Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[36]  M Schulzer,et al.  Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism , 1994, Annals of neurology.

[37]  Miguel A Hernán,et al.  Diet and Parkinson's disease: A potential role of dairy products in men , 2002, Annals of neurology.

[38]  K. Lindsted,et al.  Determinants of long-term (24-year) diet recall ability using a 21-item food frequency questionnaire. , 1989, Nutrition and cancer.

[39]  M. Singer,et al.  Nutritional Epidemiology , 2020, Definitions.

[40]  J. Gorell,et al.  Occupational Metal Exposures and the Risk of Parkinson’s Disease , 1999, Neuroepidemiology.

[41]  L. Golbe,et al.  Case-control study of early life dietary factors in Parkinson's disease. , 1988, Archives of neurology.

[42]  J. Andersen,et al.  Glutathione, iron and Parkinson's disease. , 2002, Biochemical pharmacology.

[43]  W. Willett,et al.  The use of a self-administered questionnaire to assess diet four years in the past. , 1988, American journal of epidemiology.

[44]  T. Byers,et al.  Dietary history from the distant past: a methodological study. , 1983, Nutrition and cancer.

[45]  Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. , 1999, The New England journal of medicine.

[46]  J. Growdon,et al.  Clozapine and risperidone treatment of psychosis in Parkinson's disease. , 2000, The Journal of neuropsychiatry and clinical neurosciences.